Effect of Low-Fat Diet on Development of Prostate Cancer and Akt Phosphorylation in the Hi-Myc Transgenic Mouse Model


Abstract

This study evaluated the effect of dietary fat on prostate cancer development by using the Hi-Myc mouse transgenic prostate cancer model. Hi-Myc mice develop murine prostatic intraepithelial neoplasia (mPIN) as early as 2 to 4 weeks and invasive adenocarcinoma between 6 and 9 months due to the overexpression of human c-Myc in the mouse prostate. Three-week-old male Hi-Myc mice were placed on high-fat (HF; 42% Kcal) or low-fat (LF; 12% Kcal) diets, and equal caloric intake was maintained until euthanasia at 7 months. The number of mice that developed invasive adenocarcinoma at 7 months was 27% less in the LF diet group (12/28) compared with the HF group (23/33, P < 0.05). Epithelial cells in mPIN lesions in the LF group had a significantly lower proliferative index compared with epithelial cells in the HF group (21.7% versus 28.9%, P < 0.05). During the mPIN phase of carcinogenesis (4 months), the LF group had higher serum insulin-like growth factor (IGF) binding protein-1 levels (21.0 ng/mL versus 3.2 ± 0.8 ng/mL, P < 0.05) relative to the HF group. Akt (Ser473) phosphorylation, Akt kinase activity, and phosphorylation of downstream targets of Akt in prostates were significantly reduced in the LF diet group compared with the HF group. We conclude that dietary fat reduction delays transition from mPIN to invasive cancer in this Myc-driven transgenic mouse model, possibly through suppression of the IGF-Akt pathway and decreased proliferation of mPIN epithelial cells.

Introduction

Epidemiologic studies suggest that environmental factors associated with Western life-style may promote the development of clinical prostate cancer. One such factor that has been implicated is dietary fat. A number of case-controlled and cohort studies found that increased total fat intake, increased intake of saturated and monounsaturated fat, and increased intake of linoleic acid were associated with a higher risk of developing prostate cancer (1–3), whereas other studies showed no association between dietary fat intake and prostate cancer risk (4, 5). Few studies have shown an association between ω-6 polyunsaturated fat intake and prostate cancer risk (3, 6). The mechanisms through which dietary fat may affect the development of prostate cancer remain to be defined and include effects on the insulin-like growth factor (IGF) system, sex hormone metabolism, free radical damage, and fatty acid metabolic pathways (7). Whereas animal feeding studies have shown dietary fat reduction slowed prostate cancer xenograft growth, few studies have evaluated the role of dietary fat in prostate cancer development (8, 9). Reduction of dietary fat intake lowered the incidence of prostate cancer in two rat models of prostate cancer, but these studies did not incorporate controlled feeding protocols to ensure equal caloric intake between feeding groups (10, 11). Several other studies using rat chemoprevention models found that dietary fat modification did not affect the development of prostate cancer (12–14).

Epidemiologic studies have shown that lower serum IGF-I levels and increased IGF binding protein-3 (IGFBP-3) levels are associated with decreased prostate cancer risk, but no link has yet been established between serum IGFBP-1 and prostate cancer risk (15). There is a paucity of clinical studies evaluating IGFBP-1 and prostate cancer risk, in part due to the fact that IGFBP-1 is nutritionally regulated and serum samples must be obtained in the fasting state. In human studies, dietary fat reduction combined with exercise was associated with increased serum IGFBP-1 and decreased IGF-I levels and was causally linked to decreased mitogenic effects of human serum on LNCaP cells (16). Likewise, in controlled feeding studies in mice, fat reduction was associated with increased IGFBP-1 levels, decreased IGF-I levels, and decreased prostate cancer xenograft growth (9). To date, however, no controlled feeding studies have evaluated the effects of dietary fat intake on prostate cancer prevention and IGF-axis variables. To study the chemopreventive role of dietary fat reduction in prostate cancer, we used a transgenic mouse model that overexpresses the human c-Myc oncogene in a prostate-specific manner from the ARR2/probasin promoter (17). These transgenic mice (Hi-Myc mice) develop murine prostatic intraepithelial neoplasia (mPIN) as early as 2 to 4 weeks of age and invasive adenocarcinoma of the prostate between 6 and 9 months. The Myc mouse prostate gene expression signatures share features seen in human prostate cancer development and progression (17). The primary aim of the present study was to evaluate the calorie-independent effects of dietary fat reduction on chemoprevention of prostate cancer.

Materials and Methods

Animal husbandry and feeding protocol. The experimental protocol was approved by the University of California at Los Angeles Chancellor’s Animal Research Committee, and the animals were cared for in accordance with institutional guidelines. The transgenic mice used in this study (Hi-Myc...
mice), in which the prostate specific expression of human c-Myc is driven by the rat probasin promoter with two androgen response elements (ARSs/probasin promoter), were a generous gift from Katharine Ellwood-Yen and Charles L. Sawyers (17). Mice were weaned at 21 d postbirth and randomly assigned to the low-fat (LF) or the high-fat (HF) diet and housed one mouse per cage to accurately monitor and control caloric intake. The diet was prepared by DYETS, Inc. The compositions of the diets are listed in Table 1. Initially a palatability study with ad libitum intake showed that the LF group consumed fewer calories than the HF group. Thus, the LF mice were fed ad libitum throughout the experiment, and the average daily caloric intake of the LF group was determined once per week. The HF group was given HF food to match the average daily caloric intake of the LF group thrice per week (Monday, Wednesday, and Friday). This modified pair feeding technique has provided equal caloric intake in our previous isocaloric feeding study (9). Body weight was measured weekly.

**Blood and prostate tissue collection.** Blood was collected from the retroorbital vein in all mice at 4 mo of age after a 14-h fast. The serum was separated, frozen, and stored at -80°C. All mice were euthanized at 7 mo (after a 14-h fast). Blood was collected, and urogenital organs were harvested en block, immediately rinsed, and placed in ice-cold PBS. Using a dissecting microscope, the ventral, dorsal, lateral, and anterior prostate lobes were dissected from one side and frozen in liquid nitrogen. The remainder of each prostate was fixed in 10% buffered formalin for 12 h, washed in running water, and transferred to 50% ethanol before embedding in paraffin blocks.

**Pathology.** Sections (4 μm) were obtained from the paraffin-embedded blocks and stained with H&E. Histopathological analysis to determine presence or absence of PIN and presence of invasive adenocarcinoma was performed in a blinded fashion by a single pathologist (J.S.). Luminin and smooth muscle actin immunostaining were used to define invasion through the basement membrane and fibromuscular layer using the antibodies obtained from Dako Corporation. We used criteria for distinguishing normal, mPIN, and cancer, as defined by the consensus report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium (18). The mouse prostate lobes (dorsal, lateral, ventral, and anterior lobes) were identified histologically in H&E-fixed sections using published criteria (18, 19). Neoplastic proliferation of premalignant potential or mPIN was defined as a proliferation or stratification of atypical epithelial cells showing nuclear atypia within preexisting glands usually with tufting, micropapillary, or cribriform growth pattern. Nuclear atypia was identified by the presence of nuclear hyperchromasia with chromatin clumping and presence of nucleoli. Microinvasive adenocarcinoma was the earliest form of carcinoma recognized by the presence of malignant glands penetrating through the basement membranes into the surrounding stroma. Invasive carcinoma was defined by the presence of malignant glands showing destructive growth in the prostate parenchyma. Both microinvasive and invasive cancer lesions were classified as prostate cancer for statistical analyses. The carcinomas were well differentiated with formation of discrete, well-formed glands and showed glandular differentiation classifiable as adenocarcinoma in all cases.

**Immunohistochemistry.** Ki-67 immunostaining was performed as previously described (20). A total of 400 cells, 100 cells per field, were counted for each mouse prostate, and the number of Ki-67–positive cells was scored by a single pathologist. Terminal nucleotidyl transferase-mediated nick end labeling (TUNEL) assays were performed, as previously described (20), using the Apop Tag Peroxidase In situ Apoptosis Detection Kit from Chemicon. A total of 800 cells were counted from four fields for each mouse prostate, and the number of positive nuclei was expressed as a percentage by dividing the number of positive staining nuclei by the total number of cells counted.

**Ex vivo bioassay.** LNCaP cells were obtained from American Type Culture Collection and grown in RPMI medium without phenol red (Omega Scientific) supplemented with 10% fetal bovine serum (FBS), 100 IU penicillin, 100 μg/mL streptomycin, and 4 mM/L l-glutamine (Omega Scientific). Myc-Cap cells (21) were a generous gift of Phil Watson and Katharine Ellwood-Yen and grown in DMEM supplemented with 10% FBS (Omega Scientific). LNCaP and Myc-Cap cultures were maintained at 37°C and supplemented with 5% CO2 in a humidified incubator. The mitogenic effect of mouse serum on LNCaP and Myc-Cap proliferation was studied using an in-house bioassay. The cells were plated at 5 × 104 cells per well in 96-well plate and incubated for 24 h before changing to fresh media containing 10% mouse serum or 10% FBS (control). Each serum sample from individual mouse was tested in triplicate. The cell proliferation in media containing mouse serum was measured by using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega Corporation) as previously described (9, 20) after 48 h of incubation for LNCaP and 24 h for Myc-Cap at 37°C. The data were expressed as percentage of the proliferating cells grown in media containing 10% FBS. The interassay and intraassay coefficient of variation for the ex vivo bioassay is 6.95 and 2.98, respectively.

**Measurement of mouse serum IGF-I, IGFBPs, and free and total testosterone levels.** The levels of murine IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 were measured using in-house mouse-specific ELISAs that have been described previously (22, 23) using mouse-specific antibodies and recombinant mouse IGF and IGFBP standards. The mouse IGF-I assay has a sensitivity of 0.1 ng/mL and no cross-reactivity with mouse IGF-II or human IGF-I. The intraassay and interassay coefficient of variations were <10% in the range from 1 to 10 ng/mL. The mouse IGFBP-1, IGFBP-2, and IGFBP-3 assays have sensitivities of 0.2 ng/mL and no cross-reactivity with other IGFBFs or the human homologues. The intraassay and interassay coefficient of variations were <6% and 8%, respectively, in the range from 1 to 6 ng/mL.

Serum testosterone levels were measured at 4 mo (poled serum) and 7 mo (serum from individual mice; n = 8 per group) using total testosterone ELISA from Calbiotech and free-testosterone ELISA from Immuno-Biological Laboratories, Inc.

**In vitro Akt kinase assay.** Frozen mouse prostate tissues (ventral, dorsal, and lateral lobes) were homogenized in cell lysis buffer (20 mM/L Tris (pH 7.5), 150 mM/L NaCl, 1 mM/L EDTA, 1 mM/L EGTA, 1% Triton, 2.5 mM/L sodium Pi, 1 mM/L β-glycerophosphate, 1 mM/L Na3VO4, 1 μg/mL leupeptin] with 1 μl/mg of phenylmethylsulfonyl fluoride followed by 20-s sonication (50% power) on ice. The protein concentration of the cleared lysate was determined with the bicinchoninic acid protein assay kit (Pierce) and adjusted to be the same in all samples. This lysate was used for immunoprecipitation with immobilized Akt monoclonal antibody supplied in the Akt kinase assay kit from Cell Signaling Technology. The Akt kinase assay was performed according to the manufacturer’s protocol using GSK-3 fusion protein as a substrate, and phosphorylation of GSK-3 was measured by Western blotting with anti-phospho-GSK-3α/β (Ser21/9) antibody.

### Table 1. Ingredients of experimental diets

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>LF diet</th>
<th>% energy</th>
<th>HF diet</th>
<th>% energy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corn oil</td>
<td>50</td>
<td>12.58</td>
<td>175</td>
<td>43.32</td>
</tr>
<tr>
<td>Casein</td>
<td>200</td>
<td>50.35</td>
<td>200</td>
<td>50.35</td>
</tr>
<tr>
<td>t-Cystine</td>
<td>3</td>
<td>0.75</td>
<td>3</td>
<td>0.75</td>
</tr>
<tr>
<td>t-Methionine</td>
<td>1.6</td>
<td>0.18</td>
<td>1.6</td>
<td>0.18</td>
</tr>
<tr>
<td>Sucrose</td>
<td>0</td>
<td>0.00</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Maltose dextrin</td>
<td>30</td>
<td>1.14</td>
<td>30</td>
<td>1.14</td>
</tr>
<tr>
<td>Cornstarch</td>
<td>502.9</td>
<td>79.79</td>
<td>273.2</td>
<td>77.05</td>
</tr>
<tr>
<td>Dextrose</td>
<td>105</td>
<td>10.97</td>
<td>25</td>
<td>3.97</td>
</tr>
<tr>
<td>Cellulose</td>
<td>50</td>
<td>0.00</td>
<td>50</td>
<td>0.00</td>
</tr>
<tr>
<td>AIN-93 G mineral mix*</td>
<td>35</td>
<td>0.87</td>
<td>35</td>
<td>0.87</td>
</tr>
<tr>
<td>AIN-93 vitamin mix*</td>
<td>10</td>
<td>1.07</td>
<td>10</td>
<td>1.07</td>
</tr>
<tr>
<td>Vitamin B12 supplement*</td>
<td>10</td>
<td>1.10</td>
<td>10</td>
<td>1.10</td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>2.5</td>
<td>0.60</td>
<td>2.5</td>
<td>0.60</td>
</tr>
<tr>
<td>Total</td>
<td>1000</td>
<td>100.00</td>
<td>815.3</td>
<td>100.00</td>
</tr>
</tbody>
</table>

*See ref. 50.
Western blot analysis. Mouse prostate lysate (50 μg) was subjected to SDS-PAGE followed by Western blot analysis and densitomeric quantification, as previously described (20). Antibodies for Akt, phosphorylated Akt (Ser473), p70 S6 kinase, phosphorylated p70 S6 kinase (Thr389), phosphorylated p70 S6 kinase (Thr421/Ser424), and phosphorylated GSK-3α/β (Ser21/9) were from Cell Signaling Technology and used at 1:1,000 dilution. Monoclonal antibody 9E10 was from Abgent and used to detect Myc protein. The secondary horseradish peroxidase–linked antibody was used at 1:2,000 dilutions. Personal Densitometer SI (Molecular Dynamics) and Image Quant (Amersham Biosciences) were used to quantify the Western signals.

Statistical analysis. Quantitative measures were compared between the groups (LF versus HF) using two-tailed Student’s t test calculated by Prism 3.0 software. The P values <0.05 were considered significant. The data are presented as mean ± SE. The proportions of mice with prostate cancer versus mice with mPIN and benign prostate were compared between the diet groups with Fisher’s exact test (two-sided; Splus, version 6).

Results

Slower transition from mPIN to cancer with dietary fat reduction. Throughout the 7-month study, there was no significant difference in caloric intakes or mean body weights between the LF and HF diet groups (Supplementary Fig. S1). There was a 27% reduction in the incidence of prostate cancer in the LF group compared with the HF group at the age of 7 months (12 of 28, 42.8% versus 23 of 33, 69.7%; P = 0.042; Fig. 1A). mPIN and cancerous lesions were multifocal and most prominent in the lateral prostate lobes but were also variably present in the dorsal, ventral, and anterior lobes. mPIN lesions generally comprised 15% to 30% of the affected prostate lobes, and cancer comprised ∼20% to 40% of the affected lobes. Cancerous lesions extended directly from mPIN lesions, thus demonstrating a clear transition from mPIN to cancer.

The histologic appearance of mPIN and invasive prostate cancer are shown in Fig. 1B and C.

Reduced prostate cell proliferation in LF diet group mPIN. Given that a central mechanism in Myc-induced conversion from mPIN to invasive prostate cancer may involve cell proliferation, we investigated whether dietary fat modification affected Hi-Myc mouse prostate epithelial cell proliferation by Ki-67 immunostaining (Fig. 2A and B). Epithelial cells in mPIN lesions in the LF group had a significantly lower proliferative index compared with epithelial cells in the HF group (21.7% versus 28.9%, P = 0.05; Fig. 2B). Likewise, the proliferative index of invasive cancer epithelial cells was also lower in the LF group than the HF group (25.4% versus 31.8%, P = 0.07), although the results did not reach statistical significance.

The percentage of apoptotic cells (by TUNEL staining) in mPIN lesions was similar between the LF and HF diet groups (1.3% versus 1.7%; Fig. 2C). However, in the cancer lesions the apoptotic index was lower in the LF diet group relative to HF group (2.7% versus 5.3%, P = 0.015; Fig. 2C). Prostate cancer lesions had higher proliferation and apoptosis levels relative to mPIN lesions in both diet groups (Fig. 2B and C).

Lower mitogenicity of LF group serum. The mitogenicity of LF and HF mouse serum was evaluated by measuring the cell growth of androgen-dependent cell lines, LNCaP and Myc mouse–derived Myc-CaP (21), in media containing 10% mouse serum from 7-month-old Hi-Myc mice. LNCaP and Myc-CaP cell lines had a significantly lower proliferative index compared with epithelial cells in the HF group (21.7% versus 28.9%, P = 0.05; Fig. 2B). Likewise, the proliferative index of invasive cancer epithelial cells was also lower in the LF group than the HF group (25.4% versus 31.8%, P = 0.07), although the results did not reach statistical significance.

Increased serum IGFBP-1 in LF group during the mPIN phase of cancer development. To determine if dietary fat affects
serum levels of IGF-I and IGFBP’s during the mPIN and invasive cancer phases of carcinogenesis, mouse IGF axis levels were measured at 4 months (mPIN phase) and 7 months of age (Table 2). Hi-Myc mice in the LF group had significantly higher fasting serum IGFBP-1 levels relative to the HF group at 4 months (21.0 ± 8.9 versus 3.2 ± 0.8 ng/mL; \( P = 0.05 \)) and at 7 months (6.2 ± 1.0 versus 2.0 ± 0.5 ng/mL; \( P = 0.002 \); Table 2). Fasting serum IGF-I levels were lower in the LF group relative to the HF group at 4 months (290.2 ± 35.0 versus 322.8 ± 33.0 ng/mL; \( P = 0.19 \)), although the difference was not statistically significant. Fasting serum, IGFBP-2, IGFBP-3, and IGF-I levels were similar in the LF and HF groups at 7 months of age.

**Unchanged serum testosterone levels in response to fat modification.** Given the potential for the LF diet to lower testosterone levels and affect cancer development, we measured free and total testosterone levels in serum from the 4-month-old and 7-month-old mice. At 4 months, the free and total serum testosterone levels were similar between the LF and HF groups (free testosterone, LF 3.8 pg/mL, HF 2.7 pg/mL; total testosterone, LF 1.5 ng/mL, HF 0.7 ng/mL). At 7 months, serum total testosterone levels were not significantly different between the LF and HF diet groups (LF 0.31 ± 0.13 ng/mL; HF 0.22 ± 0.049 ng/mL; \( P = 0.48 \)). Free testosterone levels at 7 months were below the level of detection of the ELISA assay in both diet groups. Given that androgen levels affect Myc transgene expression, we examined Myc protein levels in the mouse prostates by Western blot analysis and found similar levels of Myc protein expression in the LF and HF diet groups (data not shown), consistent with our finding of no significant differences in testosterone levels between the two diet groups.

**Down-regulation of Akt pathway in LF group prostate tissue.** Binding of growth factors, such as IGF-I, to their tyrosine kinase

---

**Figure 2.** Effect of dietary fat content on Hi-Myc mouse prostate cell proliferation. A, Ki-67 immunostaining of mPIN and cancer lesions of mouse prostates from the LF and HF groups. Arrows, positive cells. B, Ki-67 immunohistochemistry showed decreased cell proliferation for the LF group in both mPIN and cancer lesions. To determine the Ki67 score, 100 cells were counted in four separate high-power fields per sample (400 cells per sample), and the average Ki67-positive cells was expressed as a percentage of total cells. Columns; mean, bar; SE. mPIN, \( n = 15 \) for LF group and 13 for HF group. Cancer, \( n = 10 \) for LF group and 11 for HF group. *, \( P = 0.05 \) by Student’s \( t \) test. C, apoptosis determined by TUNEL labeling. A total of 800 cells were counted from four fields for each sample, and the number of apoptotic cells was expressed as a percentage of the total number of cells counted. mPIN, \( n = 8 \) for LF group and 10 for HF group. Cancer, \( n = 8 \) for LF group and 14 for HF group. *, \( P = 0.015 \).
receptors leads to autophosphorylation of the receptors and activation of the serine-threonine Akt kinase (protein kinase B) via phosphoinositide 3-kinase. Western blot analyses of the mouse prostate protein showed that the LF group tissue contained 62% less phosphorylated Akt (Ser473) relative to the HF group (P = 0.016; Fig. 4A). Likewise, there was a 65% reduction in Akt kinase activity in the LF group prostate relative to the HF group as measured by an in vitro kinase assay (P = 0.045; Fig. 4B). Phosphorylation of downstream targets of Akt were also reduced in the LF group prostate relative to the HF group with a 58% reduction (P = 0.005) in GSK-3 α/β (Ser21/9) phosphorylation and a 90% reduction (P = 0.0007) in p70S6K (Thr389/421/424) phosphorylation (Fig. 5A and B).

**Discussion**

In the present study, dietary fat reduction resulted in increased serum IGFBP-1 levels, down-regulation of the Akt-mTOR pathway in prostate, and delayed development of invasive murine prostate cancer. Previously, we reported that decreasing dietary fat intake slowed growth of LAPC-4 human prostate cancer xenografts in SCID mice and modulated the circulating IGF axis (9). Xenograft models are derived from late-stage or metastatic samples of human prostate cancer. Transgenic mouse models are more appropriate to study the efficacy of chemopreventive agents and mechanisms related to early tumor development. Hi-Myc transgenic mice represent a suitable model for human prostate cancer development. Myc gene amplification and overexpression are seen in ~30% of human prostate cancer (24). As well, Hi-Myc mice do not develop neuroendocrine features seen in mouse prostate cancer carcinogenesis driven by the SV40 T-antigen as in TRAMP and LADY mice (19, 25).

Mice were housed one mouse per cage, and equal caloric intake was maintained throughout the study, resulting in similar body weights between the LF and HF diet groups. Whereas two prior feeding studies using rat models of prostate cancer showed that dietary fat reduction lowered the incidence of prostate cancer, the animals in these studies were fed ad libitum, and therefore, dietary fat intake could not be differentiated from calorie intake (8, 11). In these prior studies, animals in the HF groups had higher calorie intake and increased body weight. Whereas calorie restriction and caloric excess are known to affect cancer progression, our study excluded these variables and more clearly isolated the effect of dietary fat modification on the development of prostate cancer.

IGF-I is a known mitogen to prostate cancer cells, and epidemiologic studies have linked elevated serum levels of IGF-I in young adulthood with an increased incidence of clinical prostate cancer (26–28). Of interest, a recent a case-controlled study showed that high-serum IGF-I levels at the time of prostate biopsy were excluded these variables and more clearly isolated the effect of dietary fat modification on the development of prostate cancer.

**Table 2. Fasting serum IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 concentrations of Hi-Myc mice on LF or HF diet**

<table>
<thead>
<tr>
<th>Age (mo)</th>
<th>LF (ng/mL)</th>
<th>HF (ng/mL)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>IGF-1</td>
<td>2902 ± 35.0 (n = 6)</td>
<td>322.8 ± 33.0 (n = 6)</td>
</tr>
<tr>
<td>4</td>
<td>IGFBP-1</td>
<td>21.0 ± 0.9 (n = 7)</td>
<td>3.24 ± 0.8 (n = 8)</td>
</tr>
<tr>
<td>7</td>
<td>IGF-1</td>
<td>199.8 ± 17.4 (n = 8)</td>
<td>204.8 ± 10.4 (n = 8)</td>
</tr>
<tr>
<td>7</td>
<td>IGFBP-1</td>
<td>6.2 ± 1.0 (n = 8)</td>
<td>2.0 ± 0.5 (n = 8)</td>
</tr>
<tr>
<td>7</td>
<td>IGFBP-2</td>
<td>245.3 ± 6.1 (n = 8)</td>
<td>211.0 ± 32.7 (n = 8)</td>
</tr>
<tr>
<td>7</td>
<td>IGFBP-3</td>
<td>321.8 ± 23.3 (n = 8)</td>
<td>322.9 ± 24.1 (n = 8)</td>
</tr>
</tbody>
</table>

*Indicates statistically significant difference between the two diet groups by Student's t test (two-tailed).

NOTE: The average values are presented with ±SE.
studies, possibly due to the fact that IGFBP-1 is nutritionally regulated and fasting serum specimens are required for analyses. The present study found that the LF group had increased IGFBP-1 levels (relative to the HF group) at 4 months of age during the premalignant stage of tumor development. In addition, the LF mouse serum had reduced mitogenicity on LNCaP and Myc-CaP cells in vitro compared with the HF serum. Likewise, relative to the HF group, epithelial cells of mPIN lesions in the LF group had reduced proliferation, as shown by Ki-67 immunostaining. Taken together, these data suggest that dietary fat reduction may attenuate proliferation of prostate epithelial cells in mPIN lesions via mechanisms involving the IGF axis and ultimately delay the progression to invasive prostate cancer. Given that serum IGFBP-1 levels are modifiable by dietary changes and may affect bioavailable IGF-I, serum levels of IGFBP-1 may potentially serve as a tool for achieving and monitoring therapeutic and prevention goals.

Dietary recommendations for the purpose of cancer prevention would be dramatically improved if a serum marker could be followed to assess patient compliance and responsiveness to diet intervention, much like the role of LDL cholesterol for prevention of coronary disease. Future large-scale clinical studies will determine to what degree fasting serum IGFBP-1 may serve in such a role.

Figure 4. Phosphorylated Akt levels and Akt kinase activity in HF and LF Hi-Myc mouse prostate tissue. A, Western blot analysis of prostate lysate showed marked decrease of phosphorylated Akt (Ser473) for the LF group compared with the HF group. The bands on the Western blots were scanned by a densitometer, and the phosphorylated Akt signal was normalized to total Akt bands. Values are relative densitometric units with SE; n = 6 mice for each diet group. *, P = 0.016 by Student’s t test. B, in vitro Akt kinase assay. Total Akt was immunoprecipitated from mouse prostate lysate and tested for kinase activity using GSK-3 subunit as a substrate. The resulting phosphorylated GSK-3 was detected by Western blot. The bands on the Western blots were densitometrically quantitated. n = 5 for each group. *, P = 0.045.
amounts of Myc protein for the LF and HF diet groups. Further studies are warranted, evaluating potential interactions between dietary fat modification and androgen pathways related to prostate carcinogenesis.

A number of factors that are implicated in c-Myc-mediated transformation are regulated by downstream targets of Akt and therefore may be affected by dietary fat modification. For example, hypophosphorylation of 4EBP-1 by Akt and mTOR leads to the release of eIF4E (mRNA-cap-binding protein) that is rate-limiting for G1 progression and a target of c-Myc (36). Also Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO protein (37). Activated Akt phosphorylates FoxO proteins resulting in exclusion of FoxO proteins from nuclei and subsequent degradation. In a nonphosphorylated state, FoxO factors inhibit induction of multiple Myc target genes and Myc-induced cell proliferation (37–39). The genes down-regulated by FoxO include cyclin D1, of which coexpression with Ki-67 has been reported (40–42).

Myc not only promotes cell proliferation but also sensitizes cells to various apoptotic signals, such as hypoxia, DNA damage, glucose starvation, inhibition of translation and transcription, heat shock, and chemotoxin (43, 44). The apoptotic index increases as tumors progress from mPIN to invasive cancer in Myc mice (17), in other animal models of prostate cancer (45), and in human prostate cancer (40, 46). In the present report, there was no difference in the apoptotic index in mPIN lesions in the LF and HF group, suggesting dietary fat did not significantly affect apoptosis during the mPIN phase of prostate carcinogenesis. However, of interest, prostate cancer lesions in the LF group had a lower apoptotic index relative to the cancer in the HF group. This finding was the opposite of what we expected to see, as anticancer therapies generally are associated with increased apoptosis. Prior xenograft and human serum studies showed increased apoptosis of prostate cancer cells in response to dietary fat reduction (9, 16). Data in the literature is conflicting with regards to the biological significance of apoptosis in prostate cancer. A prior retrospective clinical study found that higher apoptotic activity in prostate cancer positively correlated with higher proliferation rates, positive surgical margins, and increased risk of death from prostate cancer (40). Similar observations were made in rat models (45). Further studies are required to determine the mechanism through which fat reduction resulted in lower rates of apoptosis in prostate cancer in the Hi-Myc mouse model.

The fat used in the diets in the present study was from corn oil, which is primarily composed of linoleic acid, an ω-6 polyunsaturated fatty acid. Membrane arachidonic acid (ω-6) derived from linoleic acid is converted by the cyclooxygenase and lipoxygenase pathways to eicosanoids, such as prostaglandin E2, leukotrienes, and hydroxyl derivatives of fatty acids. These eicosanoids have been implicated in the pathogenesis of cancer and are believed to play important roles in tumor promotion, progression, and metastasis (47, 48). Whereas the present study focused on the preventative effects of lowering dietary fat in the form of corn oil on the IGF-I–Akt pathway, other factors may also play a role in the preventive effects of dietary fat modification, such as the ratio of ω-6 and ω-3 fatty acids (49). Likewise, further studies should also address if other forms of dietary fat typically found in the Western diet, including saturated fat, affect the development of prostate cancer.

In summary, our study found that lowering dietary fat (corn oil) resulted in (a) higher serum IGFBP-1 and reduced serum mitogenicity, (b) lower proliferation index of prostate epithelial cells in mPIN and invasive prostate cancer, (c) lower phosphorylated Akt protein, Akt kinase activity, and lower levels of phosphorylated GSK3 and p70S6K in murine prostate, and (d) reduced transition from mPIN to cancer. Taken together, these studies suggest that reducing intake of dietary fat from corn oil may play a role in prostate cancer prevention.
References


Effect of Low-Fat Diet on Development of Prostate Cancer and Akt Phosphorylation in the Hi-Myc Transgenic Mouse Model


Updated version  Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/68/8/3066

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2008/04/14/68.8.3066.DC1

Cited articles  This article cites 49 articles, 28 of which you can access for free at: http://cancerres.aacrjournals.org/content/68/8/3066.full.html#ref-list-1

Citing articles  This article has been cited by 11 HighWire-hosted articles. Access the articles at: /content/68/8/3066.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.